KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $78.8 million.

  • Pacira BioSciences' Depreciation & Amortization (CF) rose 4.63% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.9 million, marking a year-over-year increase of 19.59%. This contributed to the annual value of $78.8 million for FY2024, which is 4.25% up from last year.
  • Per Pacira BioSciences' latest filing, its Depreciation & Amortization (CF) stood at $78.8 million for FY2024, which was up 4.25% from $75.6 million recorded in FY2023.
  • Pacira BioSciences' Depreciation & Amortization (CF)'s 5-year high stood at $91.5 million during FY2022, with a 5-year trough of $19.9 million in FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $78.8 million (2024), whereas its average is $82.0 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 220.52% in 2022, then declined by 17.41% in 2023.
  • Over the past 5 years, Pacira BioSciences' Depreciation & Amortization (CF) (Yearly) stood at $19.9 million in 2020, then skyrocketed by 43.40% to $28.5 million in 2021, then spiked by 220.52% to $91.5 million in 2022, then declined by 17.41% to $75.6 million in 2023, then increased by 4.25% to $78.8 million in 2024.